Sulopenem etzadroxil and Probenecid

Brand names: Orlynvah ยท Active ingredient: Sulopenem Etzadroxil, Probenecid

In short: ORLYNVAH is indicated for the treatment of uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. Limitations of Use OR

Forms & strengthsORLYNVAH (sulopenem etzadroxil 500 mg and probenecid 500 mg) tablets are supplied as pink, oval-shaped, film-coated, fixed-dose, bilayer combination tablets debossed with SULO on one side and plain on the other side.
LabelIterum Therapeutics Us Limited
Label updatedFeb 09, 2026

What is Sulopenem etzadroxil and Probenecid used for?

ORLYNVAH is indicated for the treatment of uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia

coli,

Klebsiella

pneumoniae,

or Proteus

mirabilis

in adult women who have limited or no alternative oral antibacterial treatment options.

Limitations

of

Use

ORLYNVAH is not indicated for the treatment of:

Complicated urinary tract infections (cUTI) or as step-down treatment after intravenous antibacterial treatment of cUTI .

Complicated intra-abdominal infections (cIAI)) or as step-down treatment after intravenous antibacterial treatment of cIAI .

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORLYNVAH and other antibacterial drugs, ORLYNVAH should be used only to treat uUTI that are proven or strongly suspected to be caused by susceptible bacteria. Culture and susceptibility information should be utilized in selecting or modifying antibacterial therapy .

Sulopenem etzadroxil and Probenecid dosage

The recommended dosage of ORLYNVAH is one tablet (sulopenem etzadroxil 500 mg and probenecid 500 mg) orally twice daily for 5 days. Administration of ORLYNVAH with food is recommended .

Administration of ORLYNVAH is not recommended in patients with creatinine clearance (CrCL) less than 15 mL/min or patients on hemodialysis. No dosage adjustment is required for ORLYNVAH in patients with CrCL greater than or equal to15 mL/min .

If a dose of ORLYNVAH is missed, instruct patients to take the dose as soon as possible. Do not double the dose to make up for the missed dose.

How to take Sulopenem etzadroxil and Probenecid โ€” instructions & advice from the label

Allergic Reactions

Advise patients that allergic reactions, including serious allergic reactions, could occur, and that serious allergic reactions require immediate treatment. Patients should inform their healthcare provider about any previous hypersensitivity reactions to ORLYNVAH, other beta-lactam antibacterial drugs or probenecid .

Diarrhea

Advise patients that diarrhea is a common problem caused by antibacterial drugs, including ORLYNVAH, and usually resolves when the drug is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, patients should contact their healthcare provider .

Antibacterial Resistance

Patients should be counseled that ORLYNVAH should only be used to treat proven or strongly suspected susceptible uUTI. Antibacterial drugs do not treat viral infections (e.g., the common cold). When ORLYNVAH is prescribed to treat proven or strongly suspected susceptible uUTI, patients should be told that although it is common to feel better early in the course of therapy, ORLYNVAH should be taken exactly as directed. โ€ฆ

Warnings & precautions

Do not take this medicine if: ORLYNVAH is contraindicated in patients with:

โ€ข A history of hypersensitivity to the components of ORLYNVAH (sulopenem etzadroxil and probenecid) or other beta-lactam antibacterial drugs

โ€ข Known uric acid kidney stones

Concomitant use of ORLYNVAH and ketorolac tromethamine is contraindicated

Hypersensitivity reactions, specifically cases of angioedema, have been reported in patients treated with ORLYNVAH . Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs . Before therapy with ORLYNVAH is instituted, carefully inquire about previous hypersensitivity reactions to other carbapenems, cephalosporins, penicillins, or other beta-lactams because cross- hypersensitivity among beta-lactam antibacterial drugs has been reported. Severe allergic reactions and anaphylaxis have been reported with the use of probenecid (a component of ORLYNVAH). If an allergic reaction to ORLYNVAH occurs, discontinue the drug and institute appropriate supportive measures.

Clostridioides difficile-associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs with severity ranging from mild diarrhea to fatal colitis. Treatment with antibacterial agents can alter the normal flora of the colon and may permit overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. โ€ฆ

Sulopenem etzadroxil and Probenecid side effects

The following adverse reactions are described in greater detail in the Warnings and Precautions section.

Hypersensitivity Reactions

Clostridioides difficile-Associated Diarrhea

Risk of Uric Acid Kidney Stone Development

Exacerbation of Gout

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.

ORLYNVAH was evaluated in two Phase 3 controlled, multinational, randomized, double blind, double dummy clinical trials (Trial 1 and Trial 2) in adult women with uUTI. Therapy with oral ORLYNVAH tablets was administered as one tablet twice daily for 5 days . The trials included 1932 patients treated with ORLYNVAH and 1929 patients treated with comparator antibacterial drugs (ciprofloxacin or amoxicillin/clavulanate). The median age of patients treated with ORLYNVAH was 50 years, ranging between 18 and 91 years old. Patients treated with ORLYNVAH were all female (100%), predominantly White (83%) and from the United States (83%).

Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation

Serious adverse reactions occurred in 6/1932 (0.3%) of uUTI patients treated with ORLYNVAH and in 2/822 (0.2%) and 5/1107 (0.5%) of patients treated with ciprofloxacin or amoxicillin/clavulanate, respectively. โ€ฆ

Drug interactions

Probenecid (a component of ORLYNVAH) is an inhibitor of organic anion transporters 1 and 3 (OAT1/3) and may increase plasma concentrations of drugs that are dependent on OAT1/3 for elimination. Table 2 provides a list of established or potentially clinically significant drug interactions.

Concomitant

Drug/Drug

Class | Effect

on

Drug

Concentration | Recommendation

Ketorolac tromethamine | โ†‘ ketorolac tromethamine | Contraindicated

Ketoprofen | โ†‘ ketoprofen | Concomitant use is not recommended.

Indomethacin | โ†‘ indomethacin | May increase the risk of adverse reactions. Refer to drug-specific prescribing information for dosage adjustment instructions.

Naproxen | โ†‘ naproxen | May increase the risk of adverse reactions. Refer todrug-specific prescribing information for dosage adjustment instructions.

Methotrexate | โ†‘ methotrexate | If concomitant use cannot be avoided, monitor more frequently for adverse reactions associated with methotrexate as recommended in its prescribing information.

Rifampin | โ†‘ rifampin | Monitor more frequently for adverse reactionsassociated with rifampin as recommended in its prescribing information.

Lorazepam | โ†‘ lorazepam | Follow the recommended lorazepam dosage modifications outlined in its prescribing information. โ€ฆ

About this medicine

ORLYNVAH (sulopenem etzadroxil and probenecid) tablets contain sulopenem etzadroxil, a penem antibacterial drug, and probenecid, a renal tubular transport inhibitor.

The chemical name of sulopenem etzadroxil is 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1- hydroxyethyl]-7-oxo-3-[[(1R,3S)- tetrahydro-1-oxido-3-thienyl]thio]-, (2-ethyl-1-oxobutoxy)methyl ester, (5R,6S)-. See Figure 1 for sulopenem etzadroxil chemical structure and chemical formula. The molecular weight of sulopenem etzadroxil is 477.61 g/mol.

Figure

1.

Sulopenem

Etzadroxil

Chemical

Structure

and

Formula

The chemical name for probenecid is 4-[(dipropylamino) sulfonyl] benzoic acid. See Figure 2 for probenecid chemical structure and chemical formula. The molecular weight of probenecid is 285.36 g/mol.

Figure 2. โ€ฆ

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label โ€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 24c451c0-4cfb-37f3-e063-6394a90a895e. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin